Abdulraheem Yacoub, MD, is an Associate Professor of Medicine at University of Kansas Medical Center, Kansas City, MO. Dr Yacoub obtained his medical degree from the University of Jordan, Amman, Jordan, in 2003 and then completed his internship at King Hussein Cancer Center, Amman, Jordan, in 2005. He then moved to the USA where he completed both an internship and his residency in internal medicine at the University of Saint Louis, St. Louis, MO. Dr Yacoub then undertook his fellowship in hematology/oncology at the University of Arkansas for Medical Sciences, Little Rock, AR, in 2011.
Dr Yacoub has membership for various societies, namely the American Society of Hematology, the American Society of Clinical Oncology, and the Myeloproliferative Diseases Research Consortium.
Speaking on myelodysplastic syndrome, myelofibrosis, and myeloproliferative disorders
Dr Yacoub’s research interests lie primarily in myelofibrosis, myeloproliferative disorders and their treatments. His recent work has included the pivotal Phase II and Phase III clinical trials assessing the efficacy of parsaclisib and ruxolitinib in suboptimal responders with myelofibrosis.